More on Inovio Q1 results

|About: Inovio Pharmaceuticals... (INO)|By:, SA News Editor

Inovio (INO) revenues: $1.4M vs $14.3K; net loss: ($108M) (-21.3%); loss/share: ($0.05) (+16.7%); quick assets (ex-A/R): $116.8M (+122.1%).

Capital position should be sufficient to fund the firm's operations through 2017.

Management expects to report data on the Phase 2 trial for VGX-3100, SynCon immunotherapy against HPV-caused cancers and pre-cancers delivered with the Cellectra electroporation device by mid-year.

INO-5150 cancer immunotherapy Phase 1 trial to be launched in Q3. This will trigger a milestone payment from partner Roche (RHHBY).